The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer

Imagem de Miniatura
Arquivos
art_CAMPA_The_PANcreatic_Disease_ReseArch_PANDoRA_consortium_Ten_years_2023.PDF (2.47 MB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
CAMPA, Daniele
GENTILUOMO, Manuel
STEIN, Angelika
AOKI, Mateus Nobrega
OLIVERIUS, Martin
VODICKOVA, Ludmila
JAMROZIAK, Krzysztof
THEODOROPOULOS, George
PASQUALI, Claudio
GREENHALF, William
Citação
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, v.186, article ID 104020, 13p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Pancreatic cancer has an incidence that almost matches its mortality. Only a small number of risk factors and 33 susceptibility loci have been identified. so Moreover, the relative rarity of pancreatic cancer poses significant hurdles for research aimed at increasing our knowledge of the genetic mechanisms contributing to the disease. Additionally, the inability to adequately power research questions prevents small monocentric studies from being successful. Several consortia have been established to pursue a better understanding of the genetic architecture of pancreatic cancers. The Pancreatic disease research (PANDoRA) consortium is the largest in Europe. PANDoRA is spread across 12 European countries, Brazil and Japan, bringing together 29 basic and clinical research groups. In the last ten years, PANDoRA has contributed to the discovery of 25 susceptibility loci, a feat that will be instrumental in stratifying the population by risk and optimizing preventive strategies.
Palavras-chave
Pancreatic cancer, Pancreatic ductal adenocarcinoma, Pancreatic neuroendocrine tumors, Intraductal papillary mucinous neoplasms, Chronic pancreatitis, Genetic epidemiology, Consortium
URI
https://observatorio.fm.usp.br/handle/OPI/56045
Referências
  1. Amundadottir L, 2009, NAT GENET, V41, P986, DOI 10.1038/ng.429
  2. Belleau P, 2023, CANCER RES, V83, P49, DOI 10.1158/0008-5472.CAN-22-0682
  3. Blein S, 2014, FREE RADICAL RES, V48, P380, DOI 10.3109/10715762.2013.875168
  4. Bunduc S, 2022, CRIT REV ONCOL HEMAT, V169, DOI 10.1016/j.critrevonc.2021.103548
  5. Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
  6. Campa D., 2018, MITOCHONDRIAL DNA CO, DOI [10.1186/s13058-018-0955-5, DOI 10.1186/S13058]
  7. Campa D, 2020, INT J CANCER, V147, P2065, DOI 10.1002/ijc.33004
  8. Campa D, 2019, INT J CANCER, V144, P1275, DOI 10.1002/ijc.31928
  9. Campa D, 2018, INT J CANCER, V142, P290, DOI 10.1002/ijc.31047
  10. Campa D, 2017, CANCER EPIDEM BIOMAR, V26, P1349, DOI 10.1158/1055-9965.EPI-17-0075
  11. Campa D, 2016, ONCOTARGET, V7, P57011, DOI 10.18632/oncotarget.10935
  12. Campa D, 2015, INT J CANCER, V137, P2175, DOI 10.1002/ijc.29590
  13. Campa D, 2014, CANCER EPIDEM BIOMAR, V23, P2447, DOI 10.1158/1055-9965.EPI-14-0247
  14. Campa D, 2013, CANCER EPIDEM BIOMAR, V22, P320, DOI 10.1158/1055-9965.EPI-12-1182
  15. Capurso G, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.22933
  16. Carreras-Torres R, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx012
  17. Chen F, 2019, CANCER EPIDEM BIOMAR, V28, P1238, DOI 10.1158/1055-9965.EPI-18-1235
  18. Childs EJ, 2015, NAT GENET, V47, P911, DOI 10.1038/ng.3341
  19. Conti DV, 2021, NAT GENET, V53, P11, DOI 10.1038/s41588-020-00748-0
  20. Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328
  21. Dimitrakopoulos C, 2019, JAMA SURG, V154, DOI 10.1001/jamasurg.2019.0484
  22. Dixon P, 2022, GENET MED, V24, P1604, DOI 10.1016/j.gim.2022.04.020
  23. Fujitani H, 2023, EUR J CANCER PREV, V32, P286, DOI 10.1097/CEJ.0000000000000787
  24. Galeotti AA, 2021, J MED GENET, V58, P369, DOI 10.1136/jmedgenet-2020-106961
  25. Gaspar TB, 2018, GENES-BASEL, V9, DOI 10.3390/genes9050241
  26. Gentiluomo M., 2020, GERMLINE GENETIC VAR, DOI [10.1016/j.semcancer.2020.08.003, DOI 10.1016/J.SEMCANCER.2020.08.003]
  27. Gentiluomo M, 2022, NEUROENDOCRINOLOGY, V112, P1168, DOI 10.1159/000524659
  28. Gentiluomo M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87130-0
  29. Gentiluomo M, 2020, CANCER EPIDEM BIOMAR, V29, P681, DOI 10.1158/1055-9965.EPI-19-0868
  30. Gentiluomo M, 2019, MUTAGENESIS, V34, P395, DOI 10.1093/mutage/gez040
  31. Gentiluomo M, 2019, MUTAGENESIS, V34, P391, DOI 10.1093/mutage/gez032
  32. Gentiluomo M, 2019, CARCINOGENESIS, V40, P544, DOI 10.1093/carcin/bgz006
  33. Giaccherini M, 2023, INT J CANCER, V153, P373, DOI 10.1002/ijc.34383
  34. Giaccherini M, 2022, CARCINOGENESIS, V43, P728, DOI 10.1093/carcin/bgac051
  35. Giaccherini Matteo, 2021, Crit Rev Oncol Hematol, V167, P103510, DOI 10.1016/j.critrevonc.2021.103510
  36. Gioffreda D., 2021, PANCREAT CANC SUSCEP, V148, P2779, DOI [10.1002/ijc.33475., DOI 10.1002/IJC.33475]
  37. Guo F, 2023, CLIN GASTROENTEROL H, V21, P210, DOI 10.1016/j.cgh.2022.03.013
  38. Hosnijeh FS, 2014, BLOOD, V124, P530, DOI 10.1182/blood-2013-10-532085
  39. Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21601, 10.3322/caac.21551, 10.3322/caac.21387, 10.3322/caac.20073, 10.3322/caac.21708]
  40. Klein AP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02942-5
  41. Langdon RJ, 2019, CANCER EPIDEM BIOMAR, V28, P2070, DOI 10.1158/1055-9965.EPI-19-0036
  42. Levink IJM, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065097
  43. Lewis CM, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00742-5
  44. Lu Y., 2021, ASS GENETIC VARIANTS, V12, DOI [10.3389/fgene.2021.693933, DOI 10.3389/FGENE.2021.693933]
  45. Lu Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.771312
  46. Lu Y, 2020, J MED GENET, V57, P820, DOI 10.1136/jmedgenet-2019-106200
  47. Milella M, 2022, CRIT REV ONCOL HEMAT, V169, DOI 10.1016/j.critrevonc.2021.103571
  48. Mohelnikova-Duchonova B, 2017, SCI REP-UK, V7, DOI 10.1038/srep43812
  49. Nodari Ylenia, 2023, Dig Liver Dis, V55, P1417, DOI 10.1016/j.dld.2023.02.023
  50. Obazee O, 2019, INT J CANCER, V145, P686, DOI 10.1002/ijc.32127
  51. Obazee O, 2018, CARCINOGENESIS, V39, P360, DOI 10.1093/carcin/bgx150
  52. Park W, 2021, JAMA-J AM MED ASSOC, V326, P851, DOI 10.1001/jama.2021.13027
  53. Peduzzi G, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-22973-9
  54. Peduzzi G, 2021, CANCER EPIDEM BIOMAR, V30, P2342, DOI 10.1158/1055-9965.EPI-21-0353
  55. Petersen GM, 2010, NAT GENET, V42, P224, DOI 10.1038/ng.522
  56. Rachakonda PS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060870
  57. Raimondi S, 2010, BEST PRACT RES CL GA, V24, P349, DOI 10.1016/j.bpg.2010.02.007
  58. Rizzato C., 2011, PLOS ONE, P6, DOI 10.1371/journal.pone.0027921
  59. Rizzato C., 2013, ONCOL REP, V29, P1637, DOI 10.3892/or.2013.2285
  60. Rizzato C, 2016, CARCINOGENESIS, V37, P957, DOI 10.1093/carcin/bgw080
  61. Roberts E, 2023, BREAST, V67, P71, DOI 10.1016/j.breast.2023.01.003
  62. Sanderson E, 2022, NAT REV METHOD PRIME, V2, DOI 10.1038/s43586-021-00092-5
  63. Sartor H, 2020, ACTA RADIOL, V61, P1326, DOI 10.1177/0284185119900436
  64. Stott Martyn C, 2022, Fac Rev, V11, P9, DOI 10.12703/r/11-9
  65. Summers MG, 2020, EUR J CANCER, V124, P56, DOI 10.1016/j.ejca.2019.09.024
  66. Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI [10.3322/caac.21660, 10.3322/caac.21492]
  67. Szentesi A., 2021, CARCINOGENESIS, V42, P1037, DOI 10.1093/carcin/bgab057
  68. Theodoratou E, 2018, BRIT J CANCER, V119, P988, DOI 10.1038/s41416-018-0117-7
  69. Valente R, 2017, ENDOCR-RELAT CANCER, V24, P405, DOI 10.1530/ERC-17-0040
  70. Wang YX, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2220704120
  71. Wertheim-Tysarowska K, 2021, GENES-BASEL, V12, DOI 10.3390/genes12050785
  72. Wolpin BM, 2014, NAT GENET, V46, P994, DOI 10.1038/ng.3052
  73. Zhang H., 2020, NAT GENET, V52, P572, DOI 10.1038/s41588-020- 0609-2

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03